Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 20
Have your own idea? Try our Stock Screener
Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedNov 21, 2024
DataAggregated Company Financials
Companies64
- 7D-3.1%
- 3M-11.7%
- 1Y2.0%
- YTD3.0%
Over the last 7 days, the Biotech industry has dropped 4.5%, driven by a pullback from PharmaEssentia of 8.8%. Over the last year, the industry has been flat overall. As for the next few years, earnings are expected to grow by 76% per annum.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 21 Nov 2024 | NT$513.9b | NT$24.8b | -NT$10,782,551,000.00 | 38.7x | -47.7x | 20.8x |
| Sat, 19 Oct 2024 | NT$529.0b | NT$23.5b | -NT$10,829,095,000.00 | 34.8x | -48.9x | 22.5x |
| Mon, 16 Sep 2024 | NT$557.8b | NT$23.5b | -NT$10,829,095,000.00 | 32.9x | -51.5x | 23.8x |
| Wed, 14 Aug 2024 | NT$569.3b | NT$22.1b | -NT$11,348,622,000.00 | 33.5x | -50.2x | 25.7x |
| Fri, 12 Jul 2024 | NT$554.8b | NT$21.9b | -NT$11,110,643,000.00 | 43.1x | -49.9x | 25.3x |
| Sun, 09 Jun 2024 | NT$517.9b | NT$21.9b | -NT$11,110,643,000.00 | 42.6x | -46.6x | 23.6x |
| Tue, 07 May 2024 | NT$458.8b | NT$21.6b | -NT$12,502,137,000.00 | 49.8x | -36.7x | 21.2x |
| Thu, 04 Apr 2024 | NT$441.3b | NT$21.0b | -NT$10,766,949,000.00 | 51.8x | -41x | 21x |
| Sat, 02 Mar 2024 | NT$449.8b | NT$20.7b | -NT$9,885,269,000.00 | 39x | -45.5x | 21.7x |
| Mon, 29 Jan 2024 | NT$433.1b | NT$19.9b | -NT$9,830,596,000.00 | 39.8x | -44.1x | 21.7x |
| Wed, 27 Dec 2023 | NT$467.7b | NT$19.9b | -NT$9,737,975,000.00 | 43.6x | -48x | 23.5x |
| Fri, 24 Nov 2023 | NT$479.2b | NT$19.8b | -NT$9,732,662,000.00 | 42x | -49.2x | 24.1x |
| Sun, 22 Oct 2023 | NT$447.7b | NT$18.4b | -NT$10,823,013,000.00 | 44.2x | -41.4x | 24.3x |
| Tue, 19 Sep 2023 | NT$498.3b | NT$18.3b | -NT$10,776,417,000.00 | 43.2x | -46.2x | 27.2x |
| Thu, 17 Aug 2023 | NT$471.7b | NT$18.4b | -NT$10,634,765,000.00 | 42x | -44.4x | 25.6x |
| Sat, 15 Jul 2023 | NT$471.7b | NT$18.7b | -NT$10,725,166,000.00 | 44.4x | -44x | 25.3x |
| Mon, 12 Jun 2023 | NT$490.9b | NT$17.6b | -NT$11,251,141,000.00 | 43.4x | -43.6x | 27.9x |
| Wed, 10 May 2023 | NT$511.5b | NT$18.5b | -NT$9,923,392,000.00 | 47.1x | -51.5x | 27.6x |
| Fri, 07 Apr 2023 | NT$505.0b | NT$20.3b | -NT$9,157,006,000.00 | 44.4x | -55.1x | 24.8x |
| Sun, 05 Mar 2023 | NT$524.5b | NT$22.3b | -NT$7,093,875,000.00 | 38.2x | -73.9x | 23.5x |
| Tue, 31 Jan 2023 | NT$511.6b | NT$21.8b | -NT$7,778,690,000.00 | 36.3x | -65.8x | 23.5x |
| Thu, 29 Dec 2022 | NT$492.4b | NT$21.8b | -NT$7,778,690,000.00 | 37.6x | -63.3x | 22.6x |
| Sat, 26 Nov 2022 | NT$501.5b | NT$21.8b | -NT$7,522,211,000.00 | 35.2x | -66.7x | 23x |
| Mon, 24 Oct 2022 | NT$450.9b | NT$23.1b | -NT$6,633,590,000.00 | 35.1x | -68x | 19.5x |
| Wed, 21 Sep 2022 | NT$614.4b | NT$23.1b | -NT$6,633,590,000.00 | 43.2x | -92.6x | 26.6x |
| Fri, 19 Aug 2022 | NT$567.6b | NT$24.1b | -NT$5,304,443,000.00 | 32.3x | -107x | 23.5x |
| Sun, 17 Jul 2022 | NT$515.9b | NT$22.5b | -NT$5,642,821,000.00 | 29.6x | -91.4x | 22.9x |
| Tue, 14 Jun 2022 | NT$494.4b | NT$22.5b | -NT$5,642,821,000.00 | 31.8x | -87.6x | 21.9x |
| Thu, 12 May 2022 | NT$517.4b | NT$21.7b | -NT$5,693,750,000.00 | 42.1x | -90.9x | 23.9x |
| Sat, 09 Apr 2022 | NT$542.0b | NT$21.5b | -NT$5,761,086,000.00 | 30.8x | -94.1x | 25.3x |
| Mon, 07 Mar 2022 | NT$516.2b | NT$18.0b | -NT$5,619,404,000.00 | 25x | -91.9x | 28.7x |
| Wed, 02 Feb 2022 | NT$433.6b | NT$17.9b | -NT$5,532,702,000.00 | 24.7x | -78.4x | 24.2x |
| Fri, 31 Dec 2021 | NT$449.2b | NT$17.9b | -NT$5,532,702,000.00 | 25.9x | -81.2x | 25.1x |
| Sun, 28 Nov 2021 | NT$388.9b | NT$17.9b | -NT$5,579,296,000.00 | 22.9x | -69.7x | 21.7x |
Price to Earnings Ratio
-69.7x
Current Industry PE
- Investors are pessimistic on the Taiwanese Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 24.1x is higher than the industry's current PS ratio of 20.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 11% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | -0.79% | |
| Healthcare | -1.04% | |
| Biotech | -3.12% | |
| Biotech | -3.12% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 6550 Polaris Group | NT$54.00 | 5.5% +NT$2.1b | -25.0% | PS532.3x | |
| 6541 Tanvex BioPharma | NT$69.80 | 10.3% +NT$1.1b | -5.9% | PS279.6x | |
| 6808 3D Global Biotech | NT$40.15 | 11.2% +NT$311.1m | 108.6% | PS55.9x | |
| 6657 Energenesis BiomedicalLTD | NT$52.60 | 6.7% +NT$251.5m | -22.5% | PS542.7x | |
| 1783 Maxigen Biotech | NT$43.70 | 4.4% +NT$164.8m | -10.4% | PE25.1x |